Roche No Longer Developing Olesoxime to Treat Spinal Muscular Atrophy (SMA)
Roche’s lead compound to treat spinal muscular atrophy (SMA) is no more. Olesoxime is a neuroprotective agent that was purchased by Roche in 2015 from Tophos. To date, it has proven to not be effective in helping patients with either amyotrophic lateral sclerosis nor SMA.
Read More